Jefferies Financial Group Inc. Buys 475,000 Shares of MoonLake Immunotherapeutics $MLTX

Jefferies Financial Group Inc. raised its stake in MoonLake Immunotherapeutics (NASDAQ:MLTX) by 1,900.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 500,000 shares of the company’s stock after acquiring an additional 475,000 shares during the quarter. Jefferies Financial Group Inc. owned about 0.78% of MoonLake Immunotherapeutics worth $6,590,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Alliancebernstein L.P. raised its holdings in MoonLake Immunotherapeutics by 17.8% in the 2nd quarter. Alliancebernstein L.P. now owns 1,138,022 shares of the company’s stock valued at $53,715,000 after acquiring an additional 171,932 shares during the period. Schonfeld Strategic Advisors LLC bought a new position in shares of MoonLake Immunotherapeutics during the third quarter worth approximately $6,922,000. Vestal Point Capital LP increased its holdings in shares of MoonLake Immunotherapeutics by 175.0% during the second quarter. Vestal Point Capital LP now owns 550,000 shares of the company’s stock worth $25,960,000 after purchasing an additional 350,000 shares during the period. Two Sigma Investments LP bought a new position in shares of MoonLake Immunotherapeutics during the third quarter worth approximately $3,257,000. Finally, Balyasny Asset Management L.P. increased its holdings in shares of MoonLake Immunotherapeutics by 436.8% during the second quarter. Balyasny Asset Management L.P. now owns 423,170 shares of the company’s stock worth $19,974,000 after purchasing an additional 344,335 shares during the period. 93.85% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. BTIG Research reaffirmed a “buy” rating and set a $30.00 target price on shares of MoonLake Immunotherapeutics in a report on Monday, March 30th. Royal Bank Of Canada raised their target price on shares of MoonLake Immunotherapeutics from $12.00 to $13.00 and gave the stock a “sector perform” rating in a report on Monday, March 2nd. Wolfe Research raised shares of MoonLake Immunotherapeutics from an “underperform” rating to an “outperform” rating and raised their target price for the stock from $12.00 to $24.00 in a report on Monday, March 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a report on Tuesday, May 12th. Finally, Oppenheimer raised their target price on shares of MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the stock an “outperform” rating in a report on Tuesday, February 24th. Nine research analysts have rated the stock with a Buy rating, four have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $23.85.

MoonLake Immunotherapeutics Price Performance

Shares of MLTX opened at $18.19 on Tuesday. MoonLake Immunotherapeutics has a 12 month low of $5.95 and a 12 month high of $62.75. The firm’s 50 day moving average is $17.44 and its 200-day moving average is $15.87. The stock has a market capitalization of $1.30 billion, a PE ratio of -4.70 and a beta of 1.01. The company has a current ratio of 8.60, a quick ratio of 8.60 and a debt-to-equity ratio of 0.39.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last announced its earnings results on Monday, May 11th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.07). Equities research analysts forecast that MoonLake Immunotherapeutics will post -3.71 EPS for the current year.

Insider Buying and Selling

In related news, Director Bvf Partners L. P/Il sold 3,750,000 shares of MoonLake Immunotherapeutics stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $16.79, for a total value of $62,962,500.00. Following the transaction, the director directly owned 1,039,238 shares of the company’s stock, valued at $17,448,806.02. This trade represents a 78.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Da Silva Jorge Santos sold 98,127 shares of MoonLake Immunotherapeutics stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $18.41, for a total transaction of $1,806,518.07. Following the completion of the transaction, the chief executive officer directly owned 2,976,766 shares in the company, valued at $54,802,262.06. This trade represents a 3.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 3,900,000 shares of company stock worth $65,714,663 over the last three months. 12.02% of the stock is currently owned by insiders.

MoonLake Immunotherapeutics Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.